Premature Ejaculation – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Premature Ejaculation – Pipeline Review, H2 2016’, provides an overview of the Premature Ejaculation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Premature Ejaculation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Premature Ejaculation

The report reviews pipeline therapeutics for Premature Ejaculation by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Premature Ejaculation therapeutics and enlists all their major and minor projects

The report assesses Premature Ejaculation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Premature Ejaculation

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Ixchelsis Limited

NeuroHealing Pharmaceuticals Inc.

Plethora Solutions Holdings Plc

SK Chemicals Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Premature Ejaculation Overview 6

Therapeutics Development 7

Pipeline Products for Premature Ejaculation - Overview 7

Premature Ejaculation - Therapeutics under Development by Companies 8

Premature Ejaculation - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Premature Ejaculation - Products under Development by Companies 12

Premature Ejaculation - Companies Involved in Therapeutics Development 13

Allergan Plc 13

Ixchelsis Limited 14

NeuroHealing Pharmaceuticals Inc. 15

Plethora Solutions Holdings Plc 16

SK Chemicals Co., Ltd. 17

Premature Ejaculation - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Combination Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

(lidocaine + prilocaine) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

IX-01 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

modafinil - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

NCE-405 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

onabotulinumtoxin A - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Premature Ejaculation - Dormant Projects 40

Premature Ejaculation - Discontinued Products 41

Premature Ejaculation - Product Development Milestones 42

Featured News & Press Releases 42

Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation 42

Nov 11, 2014: Plethora Solutions Provides Company Update 42

Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU 43

Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment 44

Mar 11, 2014: Plethora Solutions Provides Company update 44

Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation 45

Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation 45

Jul 01, 2013: AGM Statement & PSD502 Regulatory Update 46

Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update 46

Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502 47

Dec 19, 2011: Plethora Provides Update On PSD502 48

Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation 48

May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting 49

Nov 19, 2009: Sciele Pharma Presents Pivotal Study For PSD502, The First Potential Treatment For Premature Ejaculation At The Sexual Medicine Society Of North America (SMSNA) 49

Aug 21, 2009: NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program 50

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development for Premature Ejaculation, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Premature Ejaculation – Pipeline by Allergan Plc, H2 2016 13

Premature Ejaculation – Pipeline by Ixchelsis Limited, H2 2016 14

Premature Ejaculation – Pipeline by NeuroHealing Pharmaceuticals Inc., H2 2016 15

Premature Ejaculation – Pipeline by Plethora Solutions Holdings Plc, H2 2016 16

Premature Ejaculation – Pipeline by SK Chemicals Co., Ltd., H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Assessment by Combination Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Premature Ejaculation – Dormant Projects, H2 2016 40

Premature Ejaculation – Discontinued Products, H2 2016 41

List of Figures

List of Figures

Number of Products under Development for Premature Ejaculation, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports